TY - JOUR
T1 - Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I
AU - Tietge, Uwe J.F.
AU - Maugeais, Cyrille
AU - Cain, William
AU - Grass, David
AU - Glick, Jane M.
AU - De Beer, Frederick C.
AU - Rader, Daniel J.
PY - 2000/4/7
Y1 - 2000/4/7
N2 - Plasma levels of high density lipoprotein (HDL) cholesterol and its major protein component apolipoprotein (apo) A-I are significantly reduced in both acute and chronic inflammatory conditions, but the basis for this phenomenon is not well understood. We hypothesized that secretory phospholipase A2 (sPLA2), an acute phase protein that has been found in association with HDL, promotes HDL catabolism. A series of HDL metabolic studies were performed in transgenic mice that specifically overexpress human sPLA2 but have no evidence of local or systemic inflammation. We found that HDL isolated from these mice have a significantly lower phospholipid and cholesteryl ester and significantly greater triglyceride content. The fractional catabolic rate (FCR) of 125I-HDL was significantly faster in sPLA2 transgenic mice (4.08 ± 0.01 pools/day) compared with control wild- type littermates (2.16 ± 0.48 pools/day). 125I-HDL isolated from sPLA2 transgenic mice was catabolized significantly faster than 131I-HDL isolated from wild-type mice after injection in wild-type mice (p < 0.001). Injection of 125I-tyramine-cellobiose-HDL demonstrated significantly greater degradation of HDL apolipoproteins in the kidneys of sPLA2 transgenic mice compared with control mice (p < 0.05). The fractional catabolic rate of [3H]cholesteryl ether HDL was significantly faster in sPLA2-overexpressing mice (6.48 ± 0.24 pools/day) compared with controls (4.80 ± 0.72 pools/day). Uptake of [3H] cholesteryl ether into the livers and adrenals of sPLA2 transgenic mice was significantly enhanced compared with control mice. In summary, these data demonstrate that overexpression of sPLA2 alone in the absence of inflammation causes profound alterations of HDL metabolism in vivo and are consistent with the hypothesis that sPLA2 may promote HDL catabolism in acute and chronic inflammatory conditions.
AB - Plasma levels of high density lipoprotein (HDL) cholesterol and its major protein component apolipoprotein (apo) A-I are significantly reduced in both acute and chronic inflammatory conditions, but the basis for this phenomenon is not well understood. We hypothesized that secretory phospholipase A2 (sPLA2), an acute phase protein that has been found in association with HDL, promotes HDL catabolism. A series of HDL metabolic studies were performed in transgenic mice that specifically overexpress human sPLA2 but have no evidence of local or systemic inflammation. We found that HDL isolated from these mice have a significantly lower phospholipid and cholesteryl ester and significantly greater triglyceride content. The fractional catabolic rate (FCR) of 125I-HDL was significantly faster in sPLA2 transgenic mice (4.08 ± 0.01 pools/day) compared with control wild- type littermates (2.16 ± 0.48 pools/day). 125I-HDL isolated from sPLA2 transgenic mice was catabolized significantly faster than 131I-HDL isolated from wild-type mice after injection in wild-type mice (p < 0.001). Injection of 125I-tyramine-cellobiose-HDL demonstrated significantly greater degradation of HDL apolipoproteins in the kidneys of sPLA2 transgenic mice compared with control mice (p < 0.05). The fractional catabolic rate of [3H]cholesteryl ether HDL was significantly faster in sPLA2-overexpressing mice (6.48 ± 0.24 pools/day) compared with controls (4.80 ± 0.72 pools/day). Uptake of [3H] cholesteryl ether into the livers and adrenals of sPLA2 transgenic mice was significantly enhanced compared with control mice. In summary, these data demonstrate that overexpression of sPLA2 alone in the absence of inflammation causes profound alterations of HDL metabolism in vivo and are consistent with the hypothesis that sPLA2 may promote HDL catabolism in acute and chronic inflammatory conditions.
UR - http://www.scopus.com/inward/record.url?scp=0034616026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034616026&partnerID=8YFLogxK
U2 - 10.1074/jbc.275.14.10077
DO - 10.1074/jbc.275.14.10077
M3 - Article
C2 - 10744687
AN - SCOPUS:0034616026
SN - 0021-9258
VL - 275
SP - 10077
EP - 10084
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 14
ER -